Warren Street Wealth Advisors LLC Purchases New Holdings in Amgen Inc. (NASDAQ:AMGN)

Warren Street Wealth Advisors LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 922 shares of the medical research company’s stock, valued at approximately $287,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Centricity Wealth Management LLC bought a new position in Amgen during the fourth quarter valued at about $25,000. Pinney & Scofield Inc. bought a new position in Amgen during the fourth quarter valued at about $26,000. Ritter Daniher Financial Advisory LLC DE increased its stake in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 51 shares during the period. Synergy Investment Management LLC bought a new position in Amgen during the fourth quarter valued at about $34,000. Finally, Atala Financial Inc bought a new stake in Amgen in the fourth quarter valued at about $34,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

AMGN stock opened at $287.01 on Thursday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a 50 day moving average price of $282.39 and a 200 day moving average price of $285.31. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The stock has a market capitalization of $154.33 billion, a PE ratio of 38.01, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.05 billion. During the same quarter in the previous year, the company posted $3.96 EPS. Amgen’s revenue was up 9.4% on a year-over-year basis. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on AMGN. Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Royal Bank of Canada decreased their price objective on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Erste Group Bank downgraded Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Bank of America lifted their price objective on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday, March 5th. Finally, Guggenheim began coverage on Amgen in a report on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $309.22.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.